The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


VANTAVO 70 mg/5600 IU tablets

70 mg/5600 international unit(s) Tablet

Merck Sharp & Dohme BV,EU/1/09/572/006-008

Main Information

Trade NameVANTAVO 70 mg/5600 IU tablets
Active SubstancesVitamin d3
Alendronic acid
Strength70 mg/5600 international unit(s)
Dosage FormTablet
Licence HolderMerck Sharp & Dohme BV,
Licence NumberEU/1/09/572/006-008

Group Information

ATC CodeM05BB Bisphosphonates, combinations

Status

Authorised/WithdrawnAuthorised
Licence Issued16/10/2009
Legal status*** AWAITING VALUE ***
Supply Status*** AWAITING VALUE ***
Advertising Status*** AWAITING VALUE ***
Conditions of Licence
Marketing Status

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Generics Information

Interchangeable List CodeIC0052-103-002
Interchangeable List DocumentPDF of Interchangeable List
« Back